One of the key areas for optimization in the drug development process is the discovery stage. Traditional methods are time-consuming and often produce leads that ultimately fail.

In this webinar, Dr. Brett Pickett, Assistant Professor at BYU and co-founder of Pythia Bio, and Dr. Jeremy Jones, Principal Scientist of AI-driven Drug Design (AIDD) at Simulations Plus, will discuss how comprehensive multi-omics analyses can be paired with AIDD to identify novel disease targets and rapidly develop leads for that target. They’ll also cover how to identify additional indications for existing drug candidates to strengthen their likelihood of success.

Webinar attendees will get a chance to see Dr. Pickett demonstrate the new CDIAM (Carpe – Data, Interactome, Algorithms and Machine Learning) software to efficiently analyze large, multi-omics data to identify an under-appreciated Parkinson’s Disease (PD) target. They will then see how the Simulations Plus Early Drug Discovery team uses AIDD software to quickly develop novel leads against that target, toll-like receptor 2 (TLR2). Finally, Dr. Pickett will demonstrate how to use the CDIAM platform to identify additional indications where Simulations Plus’ PPAR gamma inhibitors could find clinical utility.

Attendees can expect to increase their understanding of multi-omics analysis, specifically how this workflow can be integrated into their target identification and drug discovery processes. They will learn how AIDD can expedite their lead identification and optimization processes and what an AI-powered drug discovery project can look like.

There will be time at the end for Q&A, so be sure to register for real-time answers to your questions about AI-driven drug design and multi-omics data analysis.